- Home
- ASRV vs SKYE Comparison
ASRV vs SKYE Comparison
Compare ASRV & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRV
- SKYE
- Stock Information
- Founded
- ASRV 1983
- SKYE 2012
- Country
- ASRV United States
- SKYE United States
- Employees
- ASRV N/A
- SKYE N/A
- Industry
- ASRV Major Banks
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ASRV Finance
- SKYE Health Care
- Exchange
- ASRV Nasdaq
- SKYE Nasdaq
- Market Cap
- ASRV 48.4M
- SKYE 46.5M
- IPO Year
- ASRV N/A
- SKYE N/A
- Fundamental
- Price
- ASRV $3.07
- SKYE $1.58
- Analyst Decision
- ASRV
- SKYE Strong Buy
- Analyst Count
- ASRV 0
- SKYE 5
- Target Price
- ASRV N/A
- SKYE $14.75
- AVG Volume (30 Days)
- ASRV 39.0K
- SKYE 674.2K
- Earning Date
- ASRV 10-21-2025
- SKYE 11-10-2025
- Dividend Yield
- ASRV 3.86%
- SKYE N/A
- EPS Growth
- ASRV N/A
- SKYE N/A
- EPS
- ASRV 0.30
- SKYE N/A
- Revenue
- ASRV $53,488,000.00
- SKYE N/A
- Revenue This Year
- ASRV N/A
- SKYE N/A
- Revenue Next Year
- ASRV N/A
- SKYE N/A
- P/E Ratio
- ASRV $10.37
- SKYE N/A
- Revenue Growth
- ASRV 17.45
- SKYE N/A
- 52 Week Low
- ASRV $2.03
- SKYE $1.14
- 52 Week High
- ASRV $3.42
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- ASRV 56.36
- SKYE 38.74
- Support Level
- ASRV $3.04
- SKYE $1.42
- Resistance Level
- ASRV $3.20
- SKYE $1.62
- Average True Range (ATR)
- ASRV 0.15
- SKYE 0.10
- MACD
- ASRV -0.00
- SKYE 0.08
- Stochastic Oscillator
- ASRV 51.61
- SKYE 75.74
About ASRV AmeriServ Financial Inc.
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.